Incidence of Rhabdomyolysis Among Patients Admitted With Jimsonweed Ingestions

This study has been completed.
Information provided by:
Akron Children's Hospital Identifier:
First received: January 1, 2008
Last updated: July 25, 2008
Last verified: July 2008
Retrospective chart review to determine the presence of rhabdomyolysis among patients admitted to CHMCA from 1997-2007 with Jimsonweed ingestions and to define possible risk factors predisposing patients to the developement of Jimsonweed-associated rhabdomyolysis.


Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Incidence of Rhabdomyolysis Among Pediatric and Adolescent Patients Admitted for Jimsonweed (Datura Stramonium) Ingestions

Resource links provided by NLM:

Further study details as provided by Akron Children's Hospital:

Primary Outcome Measures:
  • The presence of rhabdomyolysis based on serum CK concentrations in patients admitted with history of Jimsonweed ingestion. [ Time Frame: From admission until discharge ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Renal function, liver function, vital signs, physical exam [ Time Frame: From admission until discharge ] [ Designated as safety issue: Yes ]

Enrollment: 46
Study Start Date: January 2008
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Patients diagnosed with rhabdomyolysis and no history of jimsonweed ingestion
Patients diagnosed with rhabdomyolysis and history of jimsonweed ingestion


Ages Eligible for Study:   up to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed with rhabdomyolysis/ myoglobinuria/ hemoglobinuria (in-patient, out-patient, ER visit) at a CHMCA facility

Inclusion Criteria:

  • admitted to CHMCA between 1/1/1997 to 12/31/2007 with a qualifying ICD-9 diagnosis code for rhabdomyolysis, myoglobinuria, and hemoglobinuria (728.88, 791.2, 791.3)or other ICD-9 codes identified during the study
  • between the ages of 0-21 years at diagnosis

Exclusion Criteria:

  • rhabdomyolysis or serum CK concentrations not actually documented
  • patient admitted to the burn center
  • patient > 21 years of age
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00592657

United States, Ohio
Children's Hospital Medical Center of Akron
Akron, Ohio, United States, 44308
Sponsors and Collaborators
Akron Children's Hospital
Principal Investigator: Martha Blackford CHMCA
  More Information

Responsible Party: Martha Blackford PharmD, CHMCA Identifier: NCT00592657     History of Changes
Other Study ID Numbers: JIMSONWEED
Study First Received: January 1, 2008
Last Updated: July 25, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Akron Children's Hospital:
retrospective chart review
Jimsonweed ingestion

Additional relevant MeSH terms:
Muscular Diseases
Musculoskeletal Diseases
Signs and Symptoms
Urination Disorders
Urologic Diseases
Urological Manifestations processed this record on November 25, 2015